195 related articles for article (PubMed ID: 35354248)
21. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
[TBL] [Abstract][Full Text] [Related]
22. PTEN/PI3K/Akt pathway alters sensitivity of T-cell acute lymphoblastic leukemia to L-asparaginase.
Hlozkova K; Hermanova I; Safrhansova L; Alquezar-Artieda N; Kuzilkova D; Vavrova A; Sperkova K; Zaliova M; Stary J; Trka J; Starkova J
Sci Rep; 2022 Mar; 12(1):4043. PubMed ID: 35260738
[TBL] [Abstract][Full Text] [Related]
23. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
Bressanin D; Evangelisti C; Ricci F; Tabellini G; Chiarini F; Tazzari PL; Melchionda F; Buontempo F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Oncotarget; 2012 Aug; 3(8):811-23. PubMed ID: 22885370
[TBL] [Abstract][Full Text] [Related]
24. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.
Silva A; Yunes JA; Cardoso BA; Martins LR; Jotta PY; Abecasis M; Nowill AE; Leslie NR; Cardoso AA; Barata JT
J Clin Invest; 2008 Nov; 118(11):3762-74. PubMed ID: 18830414
[TBL] [Abstract][Full Text] [Related]
25. ToTAL1y degraded - rapid dTAG proteolysis of TAL1 in T-cell acute lymphoblastic leukemia.
Costa JR; Mansour MR
Haematologica; 2024 May; 109(5):1325-1327. PubMed ID: 38105739
[No Abstract] [Full Text] [Related]
26. Alteration of CTCF-associated chromatin neighborhood inhibits TAL1-driven oncogenic transcription program and leukemogenesis.
Li Y; Liao Z; Luo H; Benyoucef A; Kang Y; Lai Q; Dovat S; Miller B; Chepelev I; Li Y; Zhao K; Brand M; Huang S
Nucleic Acids Res; 2020 Apr; 48(6):3119-3133. PubMed ID: 32086528
[TBL] [Abstract][Full Text] [Related]
27. microRNAs regulate TAL1 expression in T-cell acute lymphoblastic leukemia.
Correia NC; Melão A; Póvoa V; Sarmento L; Gómez de Cedrón M; Malumbres M; Enguita FJ; Barata JT
Oncotarget; 2016 Feb; 7(7):8268-81. PubMed ID: 26882564
[TBL] [Abstract][Full Text] [Related]
28. CARMA1 is required for Notch1-induced NF-κB activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia.
Zhang N; Xu J; Wang R; Pan T; Zhang H; Yin L; Yao Y; Xu L; Zhu S; Wu Q; Li Z; Liu X; Xu K; Niu M
J Mol Med (Berl); 2021 Oct; 99(10):1447-1458. PubMed ID: 34223928
[TBL] [Abstract][Full Text] [Related]
29. The enhancer RNA
Tan SH; Leong WZ; Ngoc PCT; Tan TK; Bertulfo FC; Lim MC; An O; Li Z; Yeoh AEJ; Fullwood MJ; Tenen DG; Sanda T
Blood; 2019 Jul; 134(3):239-251. PubMed ID: 31076442
[TBL] [Abstract][Full Text] [Related]
30. ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis.
Leong WZ; Tan SH; Ngoc PCT; Amanda S; Yam AWY; Liau WS; Gong Z; Lawton LN; Tenen DG; Sanda T
Genes Dev; 2017 Dec; 31(23-24):2343-2360. PubMed ID: 29326336
[TBL] [Abstract][Full Text] [Related]
31. Chromatin looping defines expression of TAL1, its flanking genes, and regulation in T-ALL.
Zhou Y; Kurukuti S; Saffrey P; Vukovic M; Michie AM; Strogantsev R; West AG; Vetrie D
Blood; 2013 Dec; 122(26):4199-209. PubMed ID: 24200685
[TBL] [Abstract][Full Text] [Related]
32. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
33. Andrographolide inhibits growth of human T-cell acute lymphoblastic leukemia Jurkat cells by downregulation of PI3K/AKT and upregulation of p38 MAPK pathways.
Yang T; Yao S; Zhang X; Guo Y
Drug Des Devel Ther; 2016; 10():1389-97. PubMed ID: 27114702
[TBL] [Abstract][Full Text] [Related]
34. Isoforms of the TAL1 transcription factor have different roles in hematopoiesis and cell growth.
Sharma A; Mistriel-Zerbib S; Najar RA; Engal E; Bentata M; Taqatqa N; Dahan S; Cohen K; Jaffe-Herman S; Geminder O; Baker M; Nevo Y; Plaschkes I; Kay G; Drier Y; Berger M; Salton M
PLoS Biol; 2023 Jun; 21(6):e3002175. PubMed ID: 37379322
[TBL] [Abstract][Full Text] [Related]
35. TGF-beta induces degradation of TAL1/SCL by the ubiquitin-proteasome pathway through AKT-mediated phosphorylation.
Terme JM; Lhermitte L; Asnafi V; Jalinot P
Blood; 2009 Jun; 113(26):6695-8. PubMed ID: 19406989
[TBL] [Abstract][Full Text] [Related]
36. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia.
Sanda T; Lawton LN; Barrasa MI; Fan ZP; Kohlhammer H; Gutierrez A; Ma W; Tatarek J; Ahn Y; Kelliher MA; Jamieson CH; Staudt LM; Young RA; Look AT
Cancer Cell; 2012 Aug; 22(2):209-21. PubMed ID: 22897851
[TBL] [Abstract][Full Text] [Related]
37. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.
Zuurbier L; Petricoin EF; Vuerhard MJ; Calvert V; Kooi C; Buijs-Gladdines JG; Smits WK; Sonneveld E; Veerman AJ; Kamps WA; Horstmann M; Pieters R; Meijerink JP
Haematologica; 2012 Sep; 97(9):1405-13. PubMed ID: 22491738
[TBL] [Abstract][Full Text] [Related]
38. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
39. FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells.
You D; Xin J; Volk A; Wei W; Schmidt R; Scurti G; Nand S; Breuer EK; Kuo PC; Breslin P; Kini AR; Nishimura MI; Zeleznik-Le NJ; Zhang J
Cell Rep; 2015 Mar; 10(12):2055-68. PubMed ID: 25801032
[TBL] [Abstract][Full Text] [Related]
40. RUNX1 is required for oncogenic
Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
